Slides
Page 1
THE CHEMOURS COMP ANY Q3 2025 EARNINGS PRESENT A TION November 7, 2025
Page 2
Chemours - Internal Use Only This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the fourth quarter of 2025, the full year 2025 and the Company’s refreshed corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the U.S. or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, changes in laws and regulations in the U.S. or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and in our Annual Report on Form 10-K for the year ended December 31, 2024. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law. We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this presentation, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flow, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flow, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position. Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP . This analysis, as well as the other information in this presentation, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this presentation may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com. Safe Harbor Statement and Other Matters 2
Page 3
Third Quarter 2025 Highlights Generated $1.5B in Net Sales and $195M in Adjusted EBITDA Published 2024 Sustainability Report detailing significant progress against 2030 Corporate Responsibility Commitment goals Announced the successful qualification of Chemours’ two-phase immersion cooling fluid by Samsung Electronics Achieved 80% YoY Net Sales growth for Opteon Refrigerants in TSS, reflecting continued strong adoption Strategic agreement with SRF Limited in India to support market needs for essential applications 3
Page 4
Chemours - Internal Use Only Third Quarter 2025 Financial Summary ($ in millions unless otherwise noted; excludes per share amounts) 1 Net (Loss) / Income attributable to The Chemours Company. 2 Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items. Please refer to the attached "GAAP Net (Loss) IncomeAttributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)” table. 3 Calculation based on diluted share count. 4 Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. Please refer to the attached “GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)” table. 5 As previously disclosed in the first quarter of 2025, certain prior period amounts have been revised to correct for certain immaterial errors as further described in our Quarterly Report on Form 10-Q for the three months ended September 30, 2025. 3Q25 3Q24 5 Y-o-Y ∆ 2Q25 Q-o-Q ∆ Net Sales $1,495 $1,508 ($13) $1,615 ($120) Net Income / (Loss) 1 $60 ($32) $92 ($381) $441 Adj. Net Income 2 $30 $61 ($31) $87 ($57) EPS 3 $0.40 ($0.22) $0.62 ($2.54) $2.94 Adj. EPS 2,3 $0.20 $0.40 ($0.20) $0.58 ($0.38) Adj. EBITDA 2,4 $195 $202 ($7) $253 ($58) Operating Cash Flow $146 $139 $7 $93 $53 Capex $41 $76 ($35) ($43) $84 Free Cash Flow $105 $63 $42 $50 $55 FCF Conversion 54% 31% 23% 20% 34% 4
Page 5
Chemours - Internal Use Only Adjusted EBITDA Bridge: 3Q25 versus 3Q24 $202 $195 $7 $18 $15($47) 3Q24 Price Volume Cost/Other Currency 3Q25 ($ in millions) Price Impacts: $7 million due to higher pricing in TSS primarily driven by stronger Opteon Refrigerant blends aftermarket demand and strong pricing in APM, in connection with increased sales into high-value applications as well as solid sales execution for our SPS Capstone product line wind down, partially offset by lower pricing globally in TT Volume Impacts: $18 million primarily driven by increased volumes in TSS’s Opteon Refrigerant blends, partially offset by decreased volumes in APM Cost/Other: ($47) million primarily driven by higher input and operational costs in TT, one-time outage impact in APM, and input cost increases driven by R32 refrigerant and liquid cooling product development costs in TSS, partially offset by lower Corporate Expenses Currency: $15 million primarily driven by favorable currency in TT 5 Refer to footnote provided on the preceding slides. See reconciliation of Non-GAAP measures in the Appendix 5 5
Page 6
Chemours - Internal Use Only $162 $139 $194 3Q23 3Q24 3Q25 Quarterly Segment Summary ($ in millions unless otherwise noted) 37% 30% 35% Net Sales 5 Adjusted EBITDA and Margin 5 (%) $436 $468 $560 3Q23 3Q24 3Q25 TSS TSS 10% 12% 4% 20% 11% 5% 5 Refer to footnote provided on the preceding slides. TT $690 $672 $612 3Q23 3Q24 3Q25 APM $343 $354 $311 3Q23 3Q24 3Q25 TT $69 $78 $25 3Q23 3Q24 3Q25 APM $68 $38 $14 3Q23 3Q24 3Q25 6
Page 7
Chemours - Internal Use Only Liquidity Position as of September 30, 2025 $553 $665 ($41) ($13) $146 $20 2Q25 Cash Balance Operating Cash Flow Capex Cash to Shareholders Other 3Q25 Cash Blance $502 Unrestricted $613 Unrestricted ($ in millions unless otherwise noted) 6 $4.2B $3.6B 4.6x Gross Debt TTM Net Leverage 11 Net Debt 10 $1.6BTotal Liquidity 9 6 $51 Restricted $52 Restricted 7 6 Total cash balances include $52 million and $51 million of restricted cash and restricted cash equivalents on Chemours’ Balance Sheets as of September 30, 2025 and June 30, 2025, respectively. Restricted cash of $51 million at the end of thesecond quarter and $52 million at the end of the third quarter includes cash and cash equivalents held in escrow under the terms of the Memorandum of Understanding (MOU) related to potential future legacy liabilities. 7 Cash to shareholders reflects $13 million in dividends paid to shareholders during the third quarter of 2025. 8 Other primarily includes favorable FX impact on cash net of debt repayments. 9 Total liquidity is calculated as the sum of $613 million unrestricted cash and cash equivalents and $953 million of revolving credit capacity, net of outstanding letters of credit. Restricted cash and restricted cash equivalents totaling $52 million is not included in this calculation. The Company announced an amendment and extension to its credit agreement in May 2025. The amended credit facility extends commitments to 2030 with a capacity of up to $1 billion until October 2026, comprised of $780 million maturing on May 2, 2030 and $220 million on October 7, 2026. 10 Net Debt, which we also refer to herein as Total Debt Principal, Net, is calculated as gross debt less unrestricted cash and cash equivalents. 11 TTM Net Leverage reflects Total Debt Principal, Net at quarter-end divided by trailing twelve months of Adjusted EBITDA. 8 7
Page 8
STRA TEGIC PROGRESS P A THWA Y TO THRIVE
Page 9
PATHWAY TO THRIVE Balanced & Disciplined Capital Allocation To Create Shareholder Value Operational Excellence ❑Manufacturing excellence as a basis for success ❑Improved and standardized operating model for consistent execution ❑Continuous improvement to adapt to changing markets Strengthening the Long-Term ❑Measurable progress on resolving legacy liabilities in the interest of stakeholders ❑Responsible manufacturing practices ❑Targeted policy efforts Enabling Growth ❑Investing smartly in selected growth projects ❑Commercial effectiveness to drive sales growth ❑Innovation and new product development Portfolio Management ❑Holistic portfolio analysis focused on distinct value creation metrics ❑Shift product mix to higher value applications in growing end markets ❑Optimize asset footprint >$250M cost reduction from 2024 to 2027 Recognizing criticality of our chemistriesDriving shareholder value>5% Sales CAGR from 2024 to 2027 9 Our Strategy
Page 10
Chemours - Internal Use Only Progress Achieved to Date PATHWAY TO THRIVE Balanced & Disciplined Capital Allocation To Create Shareholder Value Operational Excellence ✓ On track to deliver ~$125M of gross cost savings within Chemours’ control by end of 2025 across all areas of the company ✓ Operational matters have been resolved across Chemours’ sites, a key focus for the executive leadership team this quarter ✓ Launched the Chemours Business System to embed Lean principles across operations, driving safety, quality, and efficiency improvements company-wide Strengthening the Long-Term ✓ Agreed to a proposed Judicial Consent Order with the State of New Jersey to resolve all environmental claims, including PFAS statewide ✓ Drove advocacy for the importance of Chemours’ essential chemistry as a part of U.S. trade policy changes and evolving EU regulatory landscape ✓ Detailed significant progress against 2030 CRC goals in 2024 Sustainability Report ✓ EPA starts priority review for new chemicals supporting data center projects; including liquid cooling1 Enabling Growth ✓ Continued double-digit growth with 80% YoY quarterly growth in Opteon Refrigerants, with an advantaged market position to secure aftermarket share ✓ Highlighting mineral separation expertise and the current $90M of mineral sales, roughly half of which is Precision Investment Casting Zircon and Monazite, which support essential industrial and military applications ✓ Successful qualification of Chemours’ two-phase immersion cooling fluid by Samsung Electronics Portfolio Management ✓ Strategic agreement with SRF Limited in India to support market needs for essential applications ✓ Progressed APM European asset review, including the exit of SPS Capstone business, to prioritize higher return businesses and strengthen Chemours’ overall portfolio 10 1 EPA Prioritizes Review of New Chemicals Used in Data Center Projects, Supporting American Manufacturing and Technological Advancement
Page 11
Chemours - Internal Use Only 11 Accomplished the 2030 Sustainable Offerings goal 6 years early; 50% of revenue now coming from products that specifically contribute to the UN Sustainable Development Goals Reduced total process FOC emissions 76%*—on our way to a 99% or more reduction by 2030 Achieved 52%* reduction of operational GHG emissions—on track to meet our 60% reduction by 2030 Completed first Double Materiality Assessment, supporting further alignment of our sustainability priorities with stakeholder needs 2024 Sustainability Report Highlights *versus a 2018 baseline
Page 12
Q4 AND FULL YEAR GUIDANCE
Page 13
Chemours - Internal Use Only Fourth Quarter 2025 Guidance Sequential Business Outlook: Consolidated o Net Sales: Expected to decrease 10-15% sequentially o Adjusted EBITDA: Expected to range between $130 million and $160 million o Corporate Expenses as an offset to Adjusted EBITDA: Expected to range between $40 million and $45 million o Capital Expenditures: Approximately $50 million o Free Cash Flow Conversion: Expected to range 50-70% TSS o Net Sales: Expected to decline in the high-teens to low-twenties (%) sequentially, driven by overall traditional refrigerant seasonality o Adjusted EBITDA: Expected to approximate $125 million to $140 million, primarily driven by the referenced seasonality TT o Net Sales: Expected to decrease by high single-digits to low-teens (%) sequentially, driven by seasonality, regional sales mix, and near-term destocking o Adjusted EBITDA: Expected to approximate $15 million to $20 million, due to adjustments to production volumes for near-term demand signals APM o Net Sales: Expected to decrease by low single-digits (%) sequentially due to market weakness in the industrial end markets o Adjusted EBITDA: Expected to approximate $30 million to $40 million, driven by a return to normal operations at the Washington Works U.S. site CapEx ~$220M Adjusted EBITDA $745M - $770M Net Sales $5.7B - $5.8B Full Year 2025 Outlook 13
Page 14
APPENDIX 14
Page 15
Chemours - Internal Use Only TSS Segment Net Sales and Adjusted EBITDA (Unaudited)5 $139 $194 3Q24 Price/Currency Volume Cost/Other 3Q25 ($ in millions) % of total Net Sales ($ in millions) Net Sales: The 8% year-over-year volume increase was driven by stronger demand for Opteon Refrigerant blends in connection with the stationary air conditioning (AC) transition under the U.S. AIM Act, partially offset by lower volumes for Freon Refrigerant products under this regulatory transition. The 11% year-over-year increase in pricing was primarily attributed to stronger Opteon Refrigerant aftermarket demand. Adjusted EBITDA: The increase was primarily driven by volume and price increases due to increased demand for Opteon Refrigerant blends products in connection with the stationary AC regulatory transition as referenced above, partially offset by input cost increases driven by R32 paired with one-time costs associated with our liquid cooling product development. $468 $560 $57 $35 3Q24 Price/Currency Volume 3Q25 Opteon Refrigerants 66% Q3 25 % total refrigerants: Freon = 20% Opteon = 80% Q3 24 % total refrigerants: Freon = 42% Opteon = 58% Opteon Refrigerants 44% Freon Refrigerants 31% FP&O 17% 15 Freon Refrigerants 17% FP&O 25%
Page 16
Chemours - Internal Use Only TT Segment Net Sales and Adjusted EBITDA (Unaudited)5 $672 $612 ($43) ($17) 3Q24 Price/Currency Volume 3Q25 $78 $25 3Q24 Price/Currency Volume Cost/Other 3Q25 ($ in millions) Net Sales: The year-over-year decrease was primarily driven by an 8% decrease in price globally, partially offset by favorable currency movements adding a slight 1% tailwind. Volumes showed a 2% decrease globally as the global TiO2 market remains challenged. Adjusted EBITDA: The decline was driven primarily driven by the previously mentioned decrease in price paired with operational disruption costs of approximately $11 million. ($ in millions) 16
Page 17
Chemours - Internal Use Only APM Segment Net Sales and Adjusted EBITDA (Unaudited)5 $354 $311$11 ($54) 3Q24 Price/Currency Volume 3Q25 $38 $14 3Q24 Price/Currency Volume Cost/Other 3Q25 Advanced Materials 60% Performance Solutions 40% Net Sales: Total decrease of 12% year-over-year was driven by a 15% decrease in volume which was partially offset by slight price and currency tailwinds. The decrease in volume was primarily driven by operational impacts related to the now resolved outage at the Washington Works site. Adjusted EBITDA: The decrease was primarily due to the previously mentioned volume impact and outage-related approximating $20 million, partially offset by favorable pricing and currency. ($ in millions) % of total Net Sales ($ in millions) Advanced Materials 61% Performance Solutions 39% 17
Page 18
Chemours - Internal Use Only Segment Net Sales (Unaudited)5 18
Page 19
Chemours - Internal Use Only Segment Net Sales by Region (Unaudited)5 19 1 LATAM includes Mexico. 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Net sales by geographic region North America: Thermal & Specialized Solutions 292$ 319$ 258$ 207$ 271$ 308$ 256$ 194$ 233$ 336$ 316$ Titanium Technologies 262 277 273 242 246 274 270 236 267 282 252 Advanced Performance Materials 156 150 131 119 124 133 130 112 111 125 110 Other Segment 22 17 11 9 9 10 9 7 8 10 7 Total North America 732 763 673 577 650 725 665 549 619 753 685 Asia Pacific: Thermal & Specialized Solutions 53 56 42 41 39 53 55 53 53 59 69 Titanium Technologies 147 180 186 191 147 178 171 161 105 125 122 Advanced Performance Materials 147 145 133 129 105 127 138 148 115 147 138 Other Segment 2 4 3 3 3 2 3 3 2 3 3 Total Asia Pacific 349 385 364 364 294 360 367 365 275 334 332 Europe, the Middle East, and Africa: Thermal & Specialized Solutions 100 106 85 78 92 103 98 69 98 112 87 Titanium Technologies 133 147 123 116 124 130 126 131 142 156 141 Advanced Performance Materials 76 85 70 66 63 72 70 53 56 60 52 Other Segment 5 4 3 — 2 1 2 2 1 2 2 Total Europe, the Middle East, and Africa 314 342 281 260 281 306 296 255 297 330 282 Latin America (1): Thermal & Specialized Solutions 49 52 59 54 52 55 59 74 82 90 88 Titanium Technologies 90 103 108 102 74 95 105 104 83 94 97 Advanced Performance Materials 14 14 15 11 11 13 16 11 12 14 11 Other Segment 1 1 1 — — — — 1 — — — Total Latin America 154 170 183 167 137 163 180 190 177 198 196 Total net sales 1,549$ 1,660$ 1,501$ 1,368$ 1,362$ 1,554$ 1,508$ 1,359$ 1,368$ 1,615$ 1,495$ 2023 2024
Page 20
Chemours - Internal Use Only Actual and Projected Disruption & Investment Costs (Unaudited) 20 ($, millions) Q1 - Act Q2 - Act Q3 - Act Q4 - Act Total Q1 - Act Q2 - Act Q3 - Act Q4 - Guide Total Disruption Costs Thermal & Specialized Solutions (TSS) Winter Storm -$ -$ -$ -$ -$ 5$ -$ -$ -$ 5$ Titanium Technologies (TT) Impacts from Altamira Outage - 8 18 - 26 - - - - - Winter Storm Impact - - - - - 7 - - - 7 Rail Impact to Ore Mix - - - - - - 15 - - 15 Operational Disruption - - - - - - 8 11 - 19 Total TT - 8 18 - 26 7 23 11 - 41 Advanced Performance Materials (APM) Higher Deferred Maintenance Costs - - - - - 5 - - - 5 Outage/Idling Costs & Related Impacts - - - - - - - 20 4 24 Total APM - - - - - 5 - 20 4 29 Corporate Expenses Internal Review Costs 12 11 2 2 27 3 1 2 - 6 Unallocated Costs (Applied in consolidation only) - TT Transformation Plan - 11 3 2 16 1 - - - 1 Other Transformation Costs - - - - - - 2 3 5 Total Unallocated - 11 3 2 16 1 2 3 - 6 Total Costs 12$ 30$ 23$ 4$ 69$ 21$ 26$ 36$ 4$ 87$ Investment Costs TSS - Liquid Cooling & Next Generation Refrigerants 5$ 4$ 5$ 4$ 18$ 5$ 5$ 22$ 8$ 40$ 20252024
Page 21
Chemours - Internal Use Only Segment Net Sales and Adjusted EBITDA (Unaudited)5 21 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Segment Net Sales Thermal & Specialized Solutions 494$ 533$ 444$ 380$ 454$ 519$ 468$ 390$ 466$ 597$ 560$ Titanium Technologies 632 707 690 651 591 677 672 632 597 657 612 Advanced Performance Materials 393 394 349 326 303 345 354 324 294 346 311 Other Non-Reportable Segment 30 26 18 11 14 13 14 13 11 15 12 Total Company Net Sales 1,549$ 1,660$ 1,501$ 1,368$ 1,362$ 1,554$ 1,508$ 1,359$ 1,368$ 1,615$ 1,495$ Segment Adjusted EBITDA Thermal & Specialized Solutions 185$ 214$ 162$ 124$ 150$ 160$ 139$ 122$ 141$ 207$ 194$ Titanium Technologies 70 87 69 64 69 83 78 70 50 47 25 Advanced Performance Materials 84 81 68 40 30 45 38 47 32 50 14 Other Non-Reportable Segment 10 5 2 - 2 3 3 - 1 4 2 Corporate Expenses (45) (63) (54) (50) (55) (77) (54) (69) (57) (53) (38) Segment Adjusted EBITDA Margin Thermal & Specialized Solutions 37% 40% 36% 33% 33% 31% 30% 31% 30% 35% 35% Titanium Technologies 11% 12% 10% 10% 12% 12% 12% 11% 8% 7% 4% Advanced Performance Materials 21% 21% 20% 12% 10% 13% 11% 15% 11% 14% 5% Other Non-Reportable Segment 33% 19% 13% 0% 14% 23% 21% 0% 9% 27% 17% 2023 2024
Page 22
Chemours - Internal Use Only GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio5 (Page 1/2) 22 ($ in millions except per share amounts) $ amounts $ per share* $ amounts $ per share* $ amounts $ per share* $ amounts $ amounts Income (loss) before income taxes 51$ (32)$ (261)$ (209)$ 31$ Net income (loss) attributable to Chemours 60$ 0.40$ (32)$ (0.22)$ (381)$ (2.54)$ (335)$ 59$ Non-operating pension and other post-retirement benefit income (4) (0.03) (2) (0.01) (2) (0.01) (7) (6) Exchange losses, net 1 0.01 — — 4 0.03 11 23 Restructuring, asset-related, and other charges 4 0.03 43 0.29 18 0.12 61 61 Goodwill impairment charge — — 56 0.37 — — — 56 Loss on extinguishment of debt — — — — — — 1 — Gain on sales of assets and businesses, net (7) (0.05) — — — — (8) (7) Transaction costs — — — — 2 0.01 4 9 Qualified spend recovery (13) (0.09) (7) (0.05) (13) (0.09) (39) (33) Litigation-related charges 2 0.01 3 0.02 299 1.99 301 87 Environmental charges 13 0.09 — — 60 0.40 88 — Adjustments made to income taxes (23) (0.15) 5 0.03 171 1.14 150 (11) (Benefit from) provision for income taxes relating to reconciling items (3) (0.02) (5) (0.03) (71) (0.47) (81) (29) Adjusted Net Income 30$ 0.20$ 61$ 0.40$ 87$ 0.58$ 146$ 209$ Net income attributable to non-controlling interests — — 1 1 — Interest expense, net 68 68 67 268 260 Depreciation and amortization 80 73 79 311 295 All remaining provision for income taxes 17 — 19 56 12 Adjusted EBITDA 195$ 202$ 253$ 782$ 776$ September 30, June 30, September 30, Three Months Ended Three Months Ended Twelve Months Ended 2025 2024 2025 2025 2024
Page 23
Chemours - Internal Use Only GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio5 (Page 2/2) 23 ($ in millions except per share amounts) $ amounts $ per share* $ amounts $ per share* $ amounts $ per share* $ amounts $ amounts Adjusted EBITDA 195$ 202$ 253$ 782$ 776$ Total debt principal 4,185$ 4,078$ Less: Cash and cash equivalents (613) (596) Total debt principal, net 3,572$ 3,482$ Net Leverage Ratio (calculated using GAAP earnings) (17.1)x 112.3x Net Leverage Ratio (calculated using Non-GAAP earnings) 4.6x 4.5x Weighted-average number of common shares outstanding - basic 150,320,265 149,697,616 150,238,691 Weighted-average number of common shares outstanding - diluted 150,781,614 150,180,195 150,506,761 Basic earnings (loss) per share of common stock (2) 0.40$ (0.22)$ (2.54)$ Diluted earnings (loss) per share of common stock (1) (2) 0.40$ (0.22)$ (2.54)$ Adjusted basic earnings per share of common stock (2) 0.20$ 0.41$ 0.58$ Adjusted diluted earnings per share of common stock (1) (2) 0.20$ 0.40$ 0.58$ September 30, June 30, September 30, Three Months Ended Three Months Ended Twelve Months Ended 2024 (1) In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three months ended June 30, 2025 and September 30, 2024. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three months ended June 30, 2025 and September 30, 2024 as Adjusted Net Income was in a net income position. (2) Figures may not recalculate exactly due to rounding. Basic and diluted earnings (loss) per share are calculated based on unrounded numbers. * Note: $ per share columns may not sum due to rounding. 2025 2024 2025 2025
Page 24
Chemours - Internal Use Only GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation 24 1. For the nine months ended September 30, 2024, operating cash outflows includes the release of the $606 million of cash and cash equivalents deposited in the qualified settlement fund per the terms of the U.S. public water system settlement agreement. 1 ($ in millions) June 30, 2025 2024 2025 2025 2024 Cash flows provided by (used for) operating activities 146$ 139$ 93$ 127$ (771)$ Less: Purchases of property, plant, and equipment (41) (76) (43) (168) (251) Free Cash Flows 105$ 63$ 50$ (41)$ (1,022)$ Adjusted EBITDA 195 202 253 614 600 Free Cash Flow Conversion 54% 31% 20% (7)% (170)% Three Months Ended Nine Months Ended September 30, September 30,
Page 25
Chemours - Internal Use Only (In millions except per share amounts) Low High Net loss attributable to Chemours (335)$ (318)$ Restructuring, transaction, and other costs, net (1) 462 462 Adjusted Net Income 127 144 Interest expense, net 273 273 Depreciation and amortization 317 317 All remaining provision for income taxes 28 36 Adjusted EBITDA 745$ 770$ (*) The Company ’s estimates reflect its current v isibility and ex pectations based on market factors, such as currency mov ements, macro-economic factors, and end-market demand. Actual results could differ materially from these current estimates. (Estimated) Year Ending December 31, 2025 (1) Restructuring, transaction, and other costs, net includes the net benefit from income tax es relating to reconciling items and adjustments made to income tax es for the remov al of certain discrete income tax impacts. 2025 Estimated GAAP Net Income Attributable to Chemours to Estimated Adjusted Net Income, Estimated Adjusted EBITDA(*) 25
Page 26
® 2025 CHEMOURS. ALL RIGHTS RESERVED